Blue Note Therapeutics

Blue Note Therapeutics was a prescription digital therapeutics company founded in 2018 and based in San Francisco, California.

The company focused on developing software-based treatments for anxiety, depression, and cancer-related distress in patients undergoing cancer care. Their mission was to make mental health care accessible to cancer patients at any time. The company created a range of clinically validated digital therapeutics, including their flagship product, Attune, designed to address anxiety and depression symptoms related to cancer. They also developed DreAMLand, targeting anxiety and depressive symptoms in adults with acute myeloid leukemia. Blue Note partnered with Memorial Sloan Kettering Cancer Center to advance a candidate aimed at the fear of cancer recurrence. Additionally, they offered consulting services related to healthcare software and digital therapeutics, primarily serving cancer patients in the United States.